You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Gleevec and CML

Showing 1 - 25 of 514
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera Trial in Houston (Imatinib Mesylate (Gleevec))

Completed
Has Results
  • Chronic Myelomonocytic Leukemia
  • +4 more
  • Imatinib Mesylate (Gleevec)
  • Houston, Texas
    UT MD Anderson Cancer Center
Dec 7, 2021

Chronic Phase Chronic Myelogenous Leukemia Trial in Detroit, Milwaukee (Asciminib, Imatinib)

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • Detroit, Michigan
  • +1 more
May 3, 2022

Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission Trial

Recruiting
  • Chronic Myeloid Leukemia
  • +2 more
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
  • Houston, Texas
  • +3 more
Jan 25, 2022

Philadelphia Chromosome Positive CML Trial in Worldwide (imatinib mesylate)

Completed
Has Results
  • Philadelphia Chromosome Positive CML
  • imatinib mesylate
  • Chicago, Illinois
  • +9 more
Jun 3, 2021

Chronic Myelogenous Leukemia Trial in Beirut (Nilotinib)

Recruiting
  • Chronic Myelogenous Leukemia
  • Beirut, Lebanon
    American University of Beirut Medical Center
Feb 14, 2022

Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual

Terminated
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 1, 2020

Chronic Myelogenous Leukemia Patients Treated With Imatinib

Recruiting
  • Chronic Myelogenous Leukemia
  • Chart Review
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 8, 2022

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome Trial

Completed
Has Results
  • Chronic Myelogenous Leukemia
  • +3 more
  • Duarte, California
  • +100 more
Jun 8, 2021

Chronic Myeloid Leukemia Trial in Worldwide (nilotinib)

Active, not recruiting
Has Results
  • Chronic Myeloid Leukemia
  • Los Angeles, California
  • +61 more
Mar 17, 2022

The Life After Stopping Tyrosine Kinase Inhibitors Study

Completed
  • Leukemia, Myeloid, Chronic
  • Imatinib (Stopping their TKI)
  • +3 more
  • San Francisco, California
  • +15 more
Jan 3, 2023

Chronic Myeloid Leukemia Trial in Worldwide (Imatinib mesylate)

Completed
  • Chronic Myeloid Leukemia
  • Imatinib mesylate
  • MontrĂ©al, Quebec, Canada
  • +13 more
Nov 28, 2019

Eosinophilic Myeloid Tumor, Hypereosinophilic Syndrome Trial run by the National Institute of Allergy and Infectious Diseases

Recruiting
  • Eosinophilic Myeloid Neoplasm
  • Hypereosinophilic Syndrome
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

GIST and CML Trial in Worldwide (imatinib mesylate)

Active, not recruiting
  • GIST and CML
  • imatinib mesylate
  • Los Angeles, California
  • +28 more
Apr 25, 2022

TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy

Recruiting
  • Chronic Myeloid Leukemia
  • Pisa, Italy
  • +1 more
Jan 4, 2022

Hematologic Malignancy Trial in United States (BBI608, Dexamethasone, Bortezomib)

Completed
  • Hematologic Malignancy
  • Denver, Colorado
  • +7 more
Apr 4, 2022

Chronic Myelogenous Leukemia Trial in Houston (Lonafarnib (SCH66336), Imatinib Mesylate (Gleevec))

Completed
  • Chronic Myelogenous Leukemia
  • Lonafarnib (SCH66336)
  • Imatinib Mesylate (Gleevec)
  • Houston, Texas
    M.D. Anderson Cancer Center
Nov 6, 2018

Myelogenous Leukemia, Chronic, Chronic Phase Trial in Houston (Gleevec)

Terminated
Has Results
  • Myelogenous Leukemia, Chronic, Chronic Phase
  • Houston, Texas
    MD Anderson Cancer Center
Sep 11, 2018

Concomitant Medications at CML Diagnosis

Completed
  • Chronic Myeloid Leukemia
  • the prevalence of comorbid conditions
  • (no location specified)
Sep 16, 2023

Metabolic Alternation and Clinicohematological Characteristic in

Not yet recruiting
  • CML, Chronic Phase
  • Tyrosine kinase inhibitor
  • (no location specified)
Nov 6, 2023

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

Ponatinib in CML Patients in Chronic Phase

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Therapeutic drug monitoring
  • Molecular Response
  • Cagliari, Italy
  • +4 more
Nov 3, 2023

Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated

Completed
  • Chronic Myeloid Leukaemia
  • Rionero in Vulture, Potenza, Italy
  • +32 more
Oct 24, 2022

According to Molecular Identification at Diagnosis

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Next Generation Sequencing (DNA and RNA)
  • (no location specified)
Oct 28, 2022

Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Trial in Worldwide (ABL001, ABL001 +

Active, not recruiting
  • Chronic Myelogenous Leukemia
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
  • Boston, Massachusetts
  • +18 more
Jan 19, 2023

CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))

Recruiting
  • CML, Chronic Phase
  • CML, Accelerated Phase
  • HS-10382(Part 1: Dose escalation)
  • HS-10382(Part 2: Dose expansion)
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023